168 related articles for article (PubMed ID: 36163046)
1. Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma.
Xiong Y; Qi Y; Pan Z; Wang S; Li B; Feng B; Xue H; Zhao R; Li G
Cancer Cell Int; 2022 Sep; 22(1):294. PubMed ID: 36163046
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response.
Li Z; Li Y; Tian Y; Li N; Shen L; Zhao Y
Front Immunol; 2023; 14():1170539. PubMed ID: 37275863
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Relevance and Functional Implications of Thymosin Beta-10 in Glioma.
Li W; Chen J; Xiang C; Long Y; Wu K; Li J
Genet Res (Camb); 2023; 2023():5517445. PubMed ID: 38026448
[TBL] [Abstract][Full Text] [Related]
4. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
5. Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma.
Zeng J; Yang X; Yang L; Li W; Zheng Y
Respir Res; 2020 Dec; 21(1):328. PubMed ID: 33349268
[TBL] [Abstract][Full Text] [Related]
6. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
Zhang X; Ren D; Guo L; Wang L; Wu S; Lin C; Ye L; Zhu J; Li J; Song L; Lin H; He Z
Breast Cancer Res; 2017 Feb; 19(1):15. PubMed ID: 28179017
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of thymosin β10 correlates with disease progression and poor prognosis in bladder cancer.
Wang B; Wang Z; Zhang T; Yang G
Exp Ther Med; 2019 Nov; 18(5):3759-3766. PubMed ID: 31616507
[TBL] [Abstract][Full Text] [Related]
8. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.
Song C; Su Z; Guo J
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30787051
[TBL] [Abstract][Full Text] [Related]
9. TMSB10 promotes migration and invasion of cancer cells and is a novel prognostic marker for renal cell carcinoma.
Xiao R; Shen S; Yu Y; Pan Q; Kuang R; Huang H
Int J Clin Exp Pathol; 2019; 12(1):305-312. PubMed ID: 31933746
[TBL] [Abstract][Full Text] [Related]
10. TMSB10, a potential prognosis prediction biomarker, promotes the invasion and angiogenesis of gastric cancer.
Yan Z; Yan Q; Song Y; Wang L
J Gastroenterol Hepatol; 2021 Nov; 36(11):3102-3112. PubMed ID: 34114679
[TBL] [Abstract][Full Text] [Related]
11. SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma.
Zhou Q; Wei M; Shen W; Huang S; Fan J; Huang H
Front Genet; 2022; 13():899883. PubMed ID: 35910221
[No Abstract] [Full Text] [Related]
12. The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis.
Zhang S; Guo Y; Hu Y; Gao X; Bai F; Ding Q; Hou K; Wang Z; Sun X; Zhao H; Qu Z; Xu Q
Front Immunol; 2023; 14():1242972. PubMed ID: 37809064
[TBL] [Abstract][Full Text] [Related]
13. TMSB10 Promotes Progression of Clear Cell Renal Cell Carcinoma via JUN Transcription Regulation.
Wang C; He Y; You Z; Chen X
Ann Clin Lab Sci; 2022 Mar; 52(2):230-239. PubMed ID: 35414502
[TBL] [Abstract][Full Text] [Related]
14. Identification of CREB5 as a prognostic and immunotherapeutic biomarker in glioma through multi-omics pan-cancer analysis.
Wu Z; Wang X; Wu H; Du S; Wang Z; Xie S; Zhang R; Chen G; Chen H
Comput Biol Med; 2024 May; 173():108307. PubMed ID: 38547657
[TBL] [Abstract][Full Text] [Related]
15. PTEN/AKT upregulation of TMSB10 contributes to lung cancer cell growth and predicts poor survival of the patients.
Li J; Zhou S; Li H; Xu Y; Zhou N; Liu R
Biosci Biotechnol Biochem; 2021 Mar; 85(4):805-813. PubMed ID: 33686397
[TBL] [Abstract][Full Text] [Related]
16. DNMT1 maintains the methylation of miR-152-3p to regulate TMSB10 expression, thereby affecting the biological characteristics of colorectal cancer cells.
Wang C; Ma X; Zhang J; Jia X; Huang M
IUBMB Life; 2020 Nov; 72(11):2432-2443. PubMed ID: 32918845
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
18. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
19. SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis.
Chen P; Jiang Y; Liang J; Cai J; Zhuo Y; Fan H; Yuan R; Cheng S; Zhang Y
Aging (Albany NY); 2023 Aug; 15(15):7451-7475. PubMed ID: 37566748
[TBL] [Abstract][Full Text] [Related]
20. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
